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CHARACTERIZING LOST PRODUCTIVITY AND DIRECT AND INDIRECT 
COSTS OF RHEUMATOID ARTHRITIS—A LARGE, SELF-INSURED 
EMPLOYER’S PERSPECTIVE
Naim A1, Bunn W2, Allen H3
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2Navistar, Inc, Warrenville, IL, 
USA, 3Harris Allen Group, LLC, Brookline, MA, USA
OBJECTIVES: To characterize burden of illness, health care resource utilization, and 
direct and indirect costs of select auto-immune disorders. METHODS: A retrospective 
cross-sectional analysis was performed using data from Navistar, Inc. This integrated 
dataset included health care claims (medical and pharmacy), absenteeism, workers 
compensation, short and long term disability. Individuals were identiﬁed as having 
RA based on ICD-9 classiﬁcation code 714.xx. Active employees, their dependents, 
and retirees were included in the study. Indirect costs were calculated from absenteeism 
and short-term disability days using aggregate payroll data. RESULTS: 1,344 RA 
sufferers were identiﬁed among the total sample (n = 65,000). Among the RA sufferers, 
53% were retirees, 42% were dependents and 5% were active employees. 60% were 
over the age of 50 years and more than two-thirds (70%) were females. A high rate 
of comorbidities was also observed, with 40% having more than three comorbid 
conditions. The top three comorbid conditions were chronic obstructive pulmonary 
disorder, (COPD) (23%), congestive heart failure (CHF) (19%), and vascular disease 
(18%). RA sufferers used health care services at a high annual rate (ambulatory/physi-
cian ofﬁce visits = 9.9, emergency visits = 1.8). Subsequently, the annual total direct 
costs of RA were also high at $8461 per patient. Among active employees, a high rate 
of short-term disability was observed (mean = 13.8%), whereas absence days were 
observed at a mean of 4.2 days per annum. Annual total indirect costs were calculated 
to be $2963 per employee, including absenteeism ($710), short-term disability 
($1015), workers compensation ($757), and long-term disability ($340). CONCLU-
SIONS: RA presents a signiﬁcant total health care cost burden for employers. Employ-
ers should include dependents and retirees to determine the full impact of RA on total 
costs. Employees with RA miss more work days, are less productive, and tend to utilize 
disability. Prospective studies are needed to determine employee presenteeism to 
comprehensively measure productivity loss.
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COMPARISON OF MEDICAL RESOURCE USE AND COSTS ASSOCIATED 
WITH FIBROMYALGIA IN FRANCE, GERMANY AND THE UNITED 
STATES
Knight T1, Schaefer C1, Chandran A2, Zlateva G2, Goldenberg D3, Winkelmann A4, 
Perrot S5
1Covance, Gaithersburg, MD, USA, 2Pﬁzer Inc., New York, NY, USA, 3Newton-Wellesley 
Hospital, Newton, MA, USA, 4University Hospital Munich, Munich, Germany, 5Hospital Hotel 
Dieu, Paris, France
OBJECTIVES: Fibromyalgia (FM) is a chronic disorder characterized by persistent, 
widespread pain among other symptoms. This study compares FM practice patterns 
and costs across the US and Europe in routine clinical practice. METHODS: Data 
from cross-sectional, observational studies of FM subjects 18–65 years of age in the 
US and Europe (France and Germany) were analyzed. Medical resource use (MRU) 
related costs were abstracted from retrospective chart review; patient out-of-pocket 
costs and lost productivity were collected via subject self-report. Direct and indirect 
costs, related to absenteeism and disability, due to FM were calculated using standard 
costing algorithms and reported in 2009 US dollars. Descriptive statistics on select 
variables and direct and indirect medical costs to society are reported. RESULTS: 
A total of 442 subjects (203 US, 70 France, 169 Germany) were analyzed. The U.S., 
French, and German mean (SD) age was 47.9 (10.9), 51.2 (9.47), and 49.2 (9.80), 
respectively. Approximately 95% of the U.S. subjects were female compared to 83% 
in France and 80% in Germany. Approximately 40% of U.S. and French subjects 
and 44% of German subjects were employed either full- or part-time. More than 
27% of U.S. patients were disabled, compared to 11% and 3% in France and 
Germany, respectively. Approximately 6% of U.S. subjects were retired compared 
to 24% in France and 10% in Germany. The mean (SD) annual direct costs per 
subject for FM were $7974 (7341) in the U.S., $924 (862) in France and $2234 
(2641) in Germany. The mean (SD) annual indirect costs per subject in the U.S. 
were $10,697 (20,463) compared to $9,819 (18,242) in France and $7,898 (15,822) 
in Germany. CONCLUSIONS: Total direct costs contribute more to the overall US 
cost in comparison to France and Germany, but total indirect costs due to absentee-
ism and disability proportionally contribute more in these countries compared to 
the U.S.
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ANALYSIS OF DIAGNOSES RELATED GROUP NUMBER 234— 
OTHER MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE—
OPERATING ROOM PROCEDURES
Stallard R
University of Louisville, Louisville, KY, USA
OBJECTIVES: Analyze the data for statistically signiﬁcant trends in comparison 
between DRG 234 and the general population. METHODS: An experimental dataset 
is created by combining the data pertaining to DRG 234 with an equally sized random 
sample (excluding DRG 234) dataset, resulting in an experimental dataset of 5558 
patients’ entries. These data come from the 2007 Healthcare Cost and Utilization 
Project (HCUP) Kids Inpatient Database (KID). Using commercial Statistical Analysis 
Software (SAS Enterprise Guide) and code native to SAS, various analysis techniques 
will be used to describe statistical trends in these data. RESULTS: A one-way fre-
quency analysis shows that DRG 234 has a disproportionately high occurrence in the 
Hispanic population, 18.58 % in the control group compared to 12.76% in the 
experimental group. A frequency count also shows that these diagnoses most often 
occur before the ﬁrst birthday—this is a result of many ICD 9 codes being congenital 
muscoskeletal disorders categorized under DRG 234. The diagnoses and procedures 
grouped under DRG 234 tend to result in a shorter stay but are more costly in terms 
of total charges. Linear models suggest that the total charges to Asian or Paciﬁc 
Islander patients tend to be higher than the other racial categories’ mean total charges. 
CONCLUSIONS: It is suggested that further study is completed in analyzing the 
relationship between age, race, diagnoses and procedures to determine a deﬁnite 
relationship between those variables. Particular subjects that may be worthwhile to 
investigate are: The percentage of congenital conditions in Hispanic infants compared 
to the rest of the population, the particular diagnoses and procedure codes and their 
typical costs and occurrences for the different racial categories, and an analysis of how 
the various procedure and diagnosis codes being categorized in an ‘other’ group might 
skew the data, thereby introducing difﬁculties in the modeling process.
PMS17
ESTIMATION OF COSTS OF HEALTH CARE FOR PEOPLE WITH 
RHEUMATOID ARTHRITIS FOR VARYING DEGREES OF DISABILITY AS 
MEASURED BY THE HEALTH ASSESSMENT QUESTIONNAIRE IN THE 
UNITED KINGDOM
Currie CJ1, Poole CD2, Singh A3, Reynolds A4
1Cardiff University, Cardiff, Wales, UK, 2Pharmatelligence, Cardiff, UK, 3Pﬁzer, Philadelphia, 
PA, USA, 4Pﬁzer, Maidenhead, UK
OBJECTIVES: Rheumatoid arthritis (RA) confers both signiﬁcant short- and long-
term disability, and substantial background health care costs, yet cost data are scarce. 
We modeled disability in RA using covariates also available in routine, primary care 
data from which total health care cost were estimated. METHODS: In modeling dis-
ability, biologic-naïve RA cases from the UK biologics register were selected. General 
Linear Modeling (GLM) was used to predict HAQ score from demographics, co-
morbidity, polypharmacy, RA duration, BMI, smoking status and disease activity. 
Health care costs were estimated from similar incident cases with > = 1 year’s observa-
tion selected from the THIN database. Annual costs included prescriptions, consulta-
tions, and investigations from primary care and hospital episodes. An alternatve 
generalised linear model assumed a Poisson distribution, and a log-link explored the 
association between health care costs and predicted HAQ. RESULTS: Disability was 
modeled using 3,924 cases, of whom 75% were female with an average age of 58 
years (sd 14) and an average baseline HAQ of 1.80 (sd 0.72). The optimal HAQ model 
included gender, RA duration, number prior DMARDs, number of current non-
DMARD drugs, logCRP, smoking status and stroke history. The r2 value was 0.27, 
while mean prediction error was 0.15 (sd 0.30). Costs were assessed in 3,378 cases 
with similar gender balance but slightly older (mean 64 years). Their predicted HAQ 
scores ranged from 0.48 to 3.00, with a mean of 1.60 (sd 0.40). The mean total cost 
of care in this population was £1,960 per annum (sd, £1,864), with prescriptions the 
largest component (43%), followed by outpatient attendances (18%), GP consulta-
tions (16%), and hospital admissions (13%). Predicted total costs (GBP2007) ranging 
from £650 to £10,017 were calculated from EXP^(5.949+(Age*0.002)+(pHAQ*0.67
5)+(Age*pHAQ*0.003)). CONCLUSIONS: Total health care costs for RA patients 
increased exponentially across the range of estimated disability. Exclusion of support-
service costs suggests these values may be conservative.
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RHEUMATOID ARTHRITIS (RA) TREATMENT COSTS AMONG U.S. 
PATIENTS TREATED WITH INFUSED BIOLOGICS
Ogale S1, Henk HJ2
1Genentech, South San Francisco, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA
OBJECTIVES: To determine the real-world, one-year cost of RA treatment for patients 
initiating therapy with an infused biologic from a US commercial payer perspective. 
METHODS: We conducted a retrospective, administrative claims-based analysis of 
RA patients enrolled in a large U.S. managed care plan who initiated an infused RA 
biologic (inﬂiximab, abatacept, rituximab) between January 2, 2006 to January 31, 
2009. Patients ≥18 years of age, with ≥1 diagnosis of RA and continuously enrolled 
in the health plan 6 months prior to and ≥12 months following treatment initiation, 
were included. Patients with diagnoses of non-RA conditions for which the study drugs 
are used were excluded. We assumed that rituximab and abatacept patients had 
received ≥1 anti-TNF agent, and only included inﬂiximab patients who had evidence 
of a prior anti-TNF agent. Generalized linear models with a log link and gamma 
distribution were employed to compare Total RA-related costs (RA medication + 
health care services with diagnosis of RA), RA medication costs (biologics, other 
DMARDs, NSAIDs, corticosteroids) and Index biologic costs (drug + administration), 
among patients treated with each infused biologic, while controlling for demographics, 
co-morbidity score, plan type, index year, and prior RA medications (methotrexate, 
NSAIDS, corticosteroids). RESULTS: A total of 813 patients met the inclusion criteria 
(n = 156 inﬂiximab, n = 418 abatacept, n = 239 rituximab), 82% women, average 
age 52 years (SD = 11.7). During the one-year following treatment initiation adjusted 
costs were as follows: Total RA-related health care costs (Rituximab = $26,783; 
Abatacept = $24,344; Inﬂiximab = $27,053; p = 0.1249), RA medication costs (Ritux-
imab = $19,973; Abatacept = $19,000; Inﬂiximab = $20,763; p = 0.1840), and Index 
biologic costs (Rituximab = $17,638; Abatacept = $16,233; Inﬂiximab = $17,845; p 
= 0.1256). CONCLUSIONS: We did not ﬁnd a difference in one-year RA-medication 
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costs or total RA-related costs between patients starting rituximab, abatacept, or 
inﬂiximab. From a U.S. commercial payer perspective the costs associated with the 
three infused RA-biologics are similar.
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REAL-WORLD USE OF DULOXETINE FOR LOW BACK PAIN AND 
CHRONIC LOW BACK PAIN: TREATMENT PATTERN, DIRECT AND 
INDIRECT COSTS
Ivanova JI1, Birnbaum HG2, Kantor E2, Schiller M2, Johnstone B3, Faries D3, Risser R3, 
Swindle R3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Eli Lilly 
and Company, Indianapolis, IN, USA
OBJECTIVES: Examine the real-world role of duloxetine versus other treatment for 
low back pain (LBP) and chronic LBP (CLBP). METHODS: There were 753 employees 
identiﬁed, ages 18 to 64 years, with ≥1 LBP diagnosis, per HEDIS speciﬁcations, and 
≥1 duloxetine prescription within a year after LBP diagnosis from a privately-insured 
claims database (2004–2007). Employees had continuous eligibility ≥6 months before 
(baseline) and ≥6 months after index duloxetine prescription (study period). Using 
propensity score matching, duloxetine-treated employees were matched to 753 LBP 
employees (controls) who initiated another pharmacological/non-invasive LBP treat-
ment in the same month from LBP diagnosis. A subset (n = 155 each) of matched 
employees with baseline CLBP (subsequent LBP diagnosis within 3–6 months after the 
initial LBP diagnosis) was also analyzed. McNemar tests were used to compare LBP 
treatment rates. Bias-corrected bootstrapping was used to compare direct (medical and 
drug) and indirect (workloss) costs from third-party payer perspective. RESULTS: 
During the 6-month study period, duloxetine-treated employees versus controls had 
signiﬁcantly lower rates of other pharmacological therapy (e.g., 44.0% vs. 56.4% 
narcotic opioids; 29.5% vs. 40.9% NSAIDs; all p < .001) and non-invasive therapy 
(22.3% vs. 38.7% chiropractic therapy; 18.9% vs. 38.0% physical therapy; 14.2% vs. 
27.0% exercise therapy; all p < .001). Back surgery rate was lower among duloxetine-
treated employees compared with controls (1.7% vs. 2.8%, respectively; p = 0.157). 
Duloxetine-treated employees versus controls had signiﬁcantly lower 6-month indirect 
costs ($1723 vs. $2198, p = 0.004) and lower direct costs ($4935 vs. $5649, p = 0.267). 
Sensitivity analysis using multivariate analysis conﬁrmed the results. Among CLBP 
patients, duloxetine-treated employees versus controls had a lower rate of surgery 
(1.3% vs. 5.2%, p = 0.058), direct ($5519 vs. $7066, p = 0.345) and indirect costs 
($1996 vs. $2612, p = 0.191). CONCLUSIONS: Duloxetine treatment in LBP and 
CLBP employees versus other non-surgical treatment was numerically associated with 
reduced rates of non-surgical therapies, surgery, and lower direct and indirect costs.
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COST EFFECTIVENESS ANALYSIS OF MANAGING CHRONIC GOUT 
WITH FEBUOXSTAT (ULORIC) VERSUS ALLOPURINOL (ZYLOPRIM)
Rashid N1, Hay JW2
1USC School of Pharmacy, Los Angeles, CA, USA, 2University of Southern California, Los 
Angeles, CA, USA
OBJECTIVES: To evaluate the cost effectiveness of febuoxstat compared with allo-
purinol for the management of chronic gout in the United States. METHODS: Using 
the FACT trial that compared febuoxstat with allopurinol in managing chronic gout, 
a “backward induction model” was designed using a hypothetical cohort of male 
patients in the US aged 40 to 80 years. Model estimates were taken from the trial and 
existing literature. The trial demonstrated equivalent efﬁcacy for these drugs but the 
probability of a patient attaining Allopurinol Hypersensitvity Syndrome (AHS) was 
inputted and evaluated. AHS probability and total costs were obtained from literature, 
and utility value was obtained from expert opinion. These values were used for the 
base case analysis. Using a societal perspective, QALYs and costs were calculated using 
backward induction to generate lifetime incremental cost effectiveness. All costs were 
reported as 2009 US dollars, after being inﬂated using the medical component of the 
CPI. Life expectancy, QALYs, and costs were discounted at a rate of 3%. RESULTS: 
Using a societal cost effectiveness threshold of US $150,000/QALY, managing chronic 
gout using febuoxstat daily is cost effective for males aged 55 to 75 years. It becomes 
cost ineffective for males aged 40 to 50 years. Febuoxstat contributed to greater 
QALYs for all patients with AHS at 2%. A one way sensitivity analysis was performed 
using the 55 year old male patient as a base case comparison with an ICER of US 
$110,701/QALY to test uncertainties. If AHS is not considered in this model, then 
febuoxstat will be to cost ineffective throughout this analysis. CONCLUSIONS: Cur-
rently, febuoxstat is more expensive, and since they are both equally efﬁcacious, 
allopurinol should be recommended as ﬁrst line therapy. Febuoxstat can be used as a 
cost effective alternative in certain age groups, if AHS occurs.
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COST—EFFECTIVENESS OF RITUXIMAB VS ADALIMUMAB IN THE 
TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
Bynum LA, Joshi N
University of Mississippi, University, MS, USA
OBJECTIVES: To determine the cost-effectiveness of Rituximab (Rituxan) in com-
parison to the standard treatment of Adalimunab (Humira) for patients with moderate 
to severe rheumatoid arthritis. METHODS: A decision analytic model was carried out 
comparing the effectiveness and treatment costs of two treatments consisting of the 
standard care (Adalimumab) or the alternative care (Rituximab). Four outcome groups 
were deﬁned for each alternative: Effective with or without adverse events and Not 
Effective with or without adverse events. Results from clinical trials and pertinent 
literature were used to derive the model inputs. A published equation was used to 
predict quality-adjusted life years (QALYs) from the Health Assessment Questionnaire 
(HAQ) disability index. The HAQ-DI assesses the extent of the patient’s functional 
ability and has been extensively used in clinical settings. The HAQ-DI is sensitive to 
change and is a good predictor of future disability and costs. Costs included the medi-
cation acquisition cost, the physician and monitoring costs as well as the average 
adverse drug events costs. All costs were expressed in 2009 US dollars. A sensitivity 
analysis was undertaken in order to assess the uncertainty surrounding calculated 
QALY scores. RESULTS: Based on the outcome estimates of the randomized clinical 
trials as well as the acquisition, physician, monitoring and adverse drug event costs. 
The study ﬁndings indicate that the clinical beneﬁts on the change in QALY scores 
resulting in an incremental cost of $66,123.00. The sensitivity analysis conﬁrmed the 
results to be robust and are not affected by uncertainty. CONCLUSIONS: This study 
suggests that Adalimumab is more costly and less effective than Rituximab. These 
results indicate that Rituximab should be utilized for the treatment of moderate to 
severe rheumatoid arthritis.
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THE COST-EFFECTIVENESS OF PREGABALIN (LYRICA®) IN THE 
TREATMENT OF SEVERE FIBROMYALGIA IN THE UNITED STATES
Lloyd A1, Castelnuovo E1, Boomershine CS2, Choy E3, Chandran A4, Zlateva G4
1IMS Health, London, UK, 2Division of Rheumatology and Immunology, Vanderbilt University, 
Nashville, TN, USA, 3King’s Musculoskeletal Clinical Trials Unit, King’s College, London, UK, 
4Pﬁzer Inc., New York, NY, USA
OBJECTIVES: Fibromyalgia is a chronic condition manifesting with widespread pain, 
non-restorative sleep, fatigue and cognitive dysfunction. Fibromyalgia imposes high 
costs due to work loss and medical resource use. We built a decision-analytic model 
to assess the cost-effectiveness of treating severe ﬁbromyalgia with pregabalin. 
METHODS: Patients considered had Fibromyalgia Impact Questionnaire scores >59 
and pain scores >6.5 at baseline. Pregabalin 450 mg and 300 mg were compared to 
placebo, duloxetine, gabapentin, tramadol, milnacipran and amitriptyline. Patient 
response was assessed after 12 weeks of therapy: responders entered a long term model 
in which they maintained response, lost response, or dropped out. Response rates for 
pregabalin and placebo were derived from a pooled analysis of 3 randomized trials: 
response was deﬁned as a ≥30% improvement over baseline pain score and patient 
global impression of change rated much or very much improved. Response rates for 
other comparators were obtained from a systematic review of randomized controlled 
studies. Longer term outcomes were derived from an open-label follow-up extension 
of a randomised pregabalin study. The primary effectiveness endpoint was mean days 
in response. Resource use was estimated from published studies. Costs were calculated 
from a societal perspective including health care costs and productivity loss. RESULTS: 
At 12 weeks, people treated with pregabalin achieved 28 days in response compared 
to 14 with placebo. Total cost per patient was $402 higher with pregabalin 300 mg 
and $989 lower with pregabalin 450 mg compared to placebo. At 1 year, pregabalin 
300 mg was less costly and more effective than placebo, duloxetine, milnacipran or 
gabapentin: the incremental cost per additional day in response compared to tramadol 
and amitriptyline was $43 and $10 respectively. Pregabalin 450 mg gave reduced costs 
and more response days than all comparators. CONCLUSIONS: Pregabalin was 
found to be an effective therapy for severe ﬁbromyalgia patients and was cost-saving 
compared to most other ﬁbromyalgia treatments.
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ECONOMICAL EVALUATION OF ADALIMUMAB IN PATIENTS WITH 
RHEUMATOID ARTHRITIS
Vorobyev PA1, Lesnicheva MV1, Avksentyeva MV2, Alekseyeva YI2, Karateyev DY3
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2I.M. 
Sechenov Moscow Medical Academy, Moscow, Russia, 3Scientiﬁc Institute of Rheumatologyá 
Russian Academy of Medical Sciences, Moscow, Russia
OBJECTIVES: to perform economic evaluation of adalimumab + methotrexate vs 
rituximab + methotrexate and inﬂiximab + methotrexate in patients with rheumatoid 
arthritis resistant to traditional methods of treatment in Russian health care system. 
METHODS: the modeled study was performed. Data on dosing regimen, efﬁcacy and 
safety of biologics were extracted from studies ARMADA, DANCER, and ATTRACT. 
Effect was measured in proportion of patients receiving this combination achieved 
ACR 20/50/70. Cost of treatment with biologics combined with methotrexate for 24 
weeks and cost-effectiveness ratio (CER) were calculated from the Russian reimburse-
ment system point of view. RESULTS: adalimumab is more effective in patients 
achieved ACR 20 (67, 54, and 50% of patients receiving adalimumab, rituximab, and 
inﬂiximab accordingly achieved ACR 20), ACR 50 (55, 34, and 27% accordingly), 
and it is more effective that inﬂiximab and has nearly equal efﬁcacy with rituximab 
in patients achieved ACR 70 (27, 30, and 8% accordingly). The cost of treatment was 
682,229.06 rubles for adalimumab + methotrexate, 651,876.66 rubles for inﬂiximab 
+ methotrexate, and 472,906.20 rubles for rituximab + methotrexate. CER for effec-
tiveness criteria “achieving ACR 20” for adalimumab was 1,018,252.33. It was lower 
than for inﬂiximab (1,303,753.32), but higher than for rituximab (875,752.22). CER 
for effectiveness criteria “achieving ACR 50” was 1,240,416.47, 1,390,900.59, and 
2,414,358.00 accordingly, and CER for “achieving ACR 70” was 2,526,774.30, 
2,364,531.00, and 8,148,458.25 accordingly. Incremental CER for adalimumab was 
1,610,175.85 / 996,775.52 / 2,990,326.57 rubles for one patient achieved ACR 
20/50/70 compared to rituximab. CONCLUSIONS: adalimumab, used as ﬁrst line of 
therapy with biological drugs, is more economically effective in patients with rheu-
matoid arthritis resistant to standard therapy, than inﬂiximab. Rituximab seems to be 
